MedTrace Logo

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

NCT06401421 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2026-01-20

No results posted yet for this study

Summary

The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis.

Participants will be followed for up to 5.5 years.

Conditions

Interventions

DIAGNOSTIC_TEST

ctDNA MRD test

Blood and tissue samples will be collected for the ctDNA MRD test

Sponsors & Collaborators

  • NSABP Foundation Inc

    collaborator NETWORK

  • Exact Sciences Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-07
Primary Completion
2030-04-30
Completion
2030-04-30
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06401421 on ClinicalTrials.gov